<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814073</url>
  </required_header>
  <id_info>
    <org_study_id>AB06006</org_study_id>
    <nct_id>NCT00814073</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap</brief_title>
  <official_title>A 24-week With Possible Extension, Prospective, Multicentre, Randomized, Double Blind, Placebo-controlled, 2-parallel Group With a Randomization 1:1, Phase III Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to
      placebo in patients with mastocytosis with handicap.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mastocytosis is a disease characterized by mast cell invasion in various organs. Mast cells
      are bone marrow derived cells which produce histamine and other substances causing allergic
      and anaphylactic reactions. Accumulation of mast cells in body organs can inhibit the
      functionality of the organ and eventually cause degeneration.

      Mutations of the mast cell growth factor receptor (KIT protein, the product of the c-Kit
      proto-oncogene) might be found in patients with mastocytosis.

      Masitinib (AB1010) is a tyrosine kinase inhibitor (TKI), selectively and effectively
      inhibiting c-kit. Its effect may include inhibition of cell proliferation, inhibition of cell
      cycle progression and induction of apoptosis resulting in the reduction of mast cell
      accumulation in body tissues. This drug is thereby specific to mastocytosis and active in
      slowing or reducing the number of mast cells particularly in aggressive forms of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Responder rate at week 24</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response in mastocytosis variables (pruritus, flushes, depression or asthenia), mictions and stools per day, patient score and assessments, patients without handicap, mast cell infiltration , serum tryptase level, safety profile</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Smouldering Systemic Mastocytosis</condition>
  <condition>Indolent Systemic Mastocytosis</condition>
  <condition>Cutaneous Mastocytosis With Handicap</condition>
  <condition>Mastocytosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib (AB1010) 6 mg/kg/day per os</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib (AB1010)</intervention_name>
    <description>masitinib (AB1010) 6 mg/kg/day per os</description>
    <arm_group_label>1</arm_group_label>
    <other_name>AB1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with one of the following documented mastocytosis as per WHO classification:
             Smouldering Systemic Mastocytosis, Indolent Systemic Mastocytosis, Cutaneous
             Mastocytosis

          2. Patient with documented mastocytosis and evaluable disease based upon histological
             criteria: typical infiltrates of mast cells in a multifocal or diffuse pattern in skin
             and/or bone marrow biopsy

          3. Patient with documented treatment failure of his/her handicap(s) with at least one of
             the following therapy used at optimized dose: Anti H1, Anti H2, Proton pump inhibitor,
             Osteoclast inhibitor, Cromoglycate Sodium, Antileukotriene

          4. Handicapped status defined as at least two of the following handicaps, including at
             least one among pruritus, flushes, depression and asthenia: pruritus score ≥ 6, number
             of flushes per week ≥ 7, Hamilton rating scale (depression) ≥ 10, number of stools per
             day ≥ 4, number of mictions per day ≥ 8, Fatigue Impact Scale total score (asthenia) ≥
             40

          5. Patients with OPA &gt; 2 (moderate to intolerable general handicap)

          6. Male or female patient with age ≥ 18 years

        Exclusion Criteria:

          1. Patient with one of the following mastocytosis: Systemic Mastocytosis with an
             Associated clonal Hematologic Non Mast cell lineage Disease (SM-AHNMD), Mast cell
             leukemia (MCL), Aggressive systemic mastocytosis (ASM)

          2. Previous treatment with any Tyrosine Kinase Inhibitor

          3. Patient presenting with at least one of the following feature: ischemic heart disease,
             cardiac failure, conduction disorders or arrythmia

          4. Patient with any condition that the physician judges could be detrimental to subjects
             participating in this study; including any clinically important deviations from normal
             clinical laboratory values or concurrent medical events Previous treatment

          5. Change in the symptomatic treatment of mastocytosis or administration of any new
             treatment of mastocytosis within 4 weeks prior to baseline

          6. Treatment with any investigational agent within 4 weeks prior to baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Lortholary, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Necker, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Lortholary, M.D., Ph.D.</last_name>
    <phone>+33 (0)1 44 38 15 70</phone>
    <email>olivier.lortholary@nck.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis Health System , Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIU Fu-Tong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Centre</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital des Hauts Clos</name>
      <address>
        <city>Troyes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>December 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2008</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mastocytosis with handicap</keyword>
  <keyword>Mastocytosis</keyword>
  <keyword>Smouldering systemic mastocytosis</keyword>
  <keyword>Indolent systemic mastocytosis</keyword>
  <keyword>Cutaneous mastocytosis</keyword>
  <keyword>Mast cell</keyword>
  <keyword>Mast cell infiltration</keyword>
  <keyword>Skin</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Flushes</keyword>
  <keyword>c-kit</keyword>
  <keyword>c-kit mutation</keyword>
  <keyword>Wild Type</keyword>
  <keyword>Mutation Asp-816-Val(D816V)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Mastocytosis, Cutaneous</mesh_term>
    <mesh_term>Mastocytoma</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 17, 2015</submitted>
    <returned>January 25, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

